Gross Profit: Revenues from operations less the associated costs.
Karyopharm Therapeutics Inc. (KPTI) had Gross Profit of $33.72M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$35.07M |
|
$-22.39M |
|
$1.34M |
|
|
Gross Profit |
$33.72M |
$61.83M |
|
$-26.76M |
|
$4.37M |
|
$-22.39M |
|
$-22.39M |
|
$-22.39M |
|
$-22.39M |
|
$-22.39M |
|
$-22.39M |
|
$-26.76M |
|
$-24.38M |
|
22.01M |
|
24.71M |
|
$-1.02 |
|
$-1.24 |
|
| Balance Sheet Financials | |
$126.33M |
|
$0.09M |
|
$5.08M |
|
$131.42M |
|
$117.30M |
|
$192.16M |
|
$279.76M |
|
$397.06M |
|
$-265.65M |
|
$-265.65M |
|
$-265.65M |
|
22.54M |
|
| Cash Flow Statement Financials | |
$-22.73M |
|
$3.20M |
|
$49.80M |
|
$60.89M |
|
$91.17M |
|
$30.28M |
|
$3.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.08 |
|
-- |
|
-- |
|
-2.61 |
|
-0.84 |
|
96.16% |
|
-76.31% |
|
-76.31% |
|
-- |
|
-63.85% |
|
-63.86% |
|
$-22.73M |
|
-- |
|
-- |
|
-- |
|
0.27 |
|
0.37 |
|
1.50 |
|
59.95 |
|
8.43% |
|
8.43% |
|
-17.04% |
|
30.47% |
|
$-11.78 |
|
$-0.92 |
|
$-0.92 |
|